In direct-compression B-complex tablet manufacture, calcium D-pantothenate is introduced after the riboflavin and niacinamide granulated phases because its calcium content can shift the moisture balance of the pre-blend and its particle-size distribution influences weight uniformity through the forced feeder. A label claim of 10 mg pantothenic acid per tablet corresponds to 10.87 mg calcium D-pantothenate using the pharmacopeial equivalence factor of approximately 0.92 pantothenic acid on the dried calcium salt. Across adult and geriatric B-complex lines, the addition level for label claims of 5 mg to 100 mg pantothenic acid per unit therefore ranges from 5.43 mg to 108.7 mg calcium D-pantothenate per tablet or capsule. In a 600 mg core, that range is approximately 0.9% w/w to 18.1% w/w, which places the compound either in a low-assay direct-blend fraction or a higher-loading pregranulation fraction. Compliance for the API rests on the USP calcium pantothenate monograph assay specification of 98.0–102.0% on the dried basis, and finished dosage release typically includes USP <905> for content uniformity, USP <711> for dissolution, and USP <2040> for disintegration, within 21 CFR 211 manufacturing controls.

On production-scale rotary tablet presses, precompression force is held between 1 kN and 3 kN and main compression is adjusted to target tablet hardness of 60–120 N; ejection force is monitored because calcium D-pantothenate blends can pick up moisture when the processing room exceeds 60% RH, producing punch filming and weight variation above 2% RSD. When the blend contains thiamine hydrochloride or other hygroscopic B vitamins, roller compaction with an 0.8 mm granulator screen is preferred before final compression. For hard gelatin capsules, a dosator or tamping-pin machine is fed after bin blending at 15–25 rpm; fumed silica at 0.5–1.0% is used when the calcium D-pantothenate fraction exceeds 10% w/w to maintain powder flow. The terminal finished dosage forms include uncoated and film-coated B-complex tablets, biotin–pantothenate combination tablets, and two-piece hard gelatin capsules intended for adult multivitamin oil-free lines.

How Does Calcium D-Pantothenate Behave in Effervescent Granule Systems Under Moisture Stress?

Effervescent dosage forms impose a residual moisture constraint that is stricter than that for conventional granules because free water initiates the citric-acid–sodium-bicarbonate reaction before dissolution. In a 3.0 g single-dose effervescent tablet containing 10–50 mg pantothenic acid per dose, the calcium D-pantothenate charge is 10.87–54.35 mg, equivalent to 0.36–1.81% w/w. Granulation is performed with anhydrous ethanol or isopropyl alcohol containing 3–5% w/w PVP K30; aqueous granulation is excluded because the localized pH below 4.0 in the presence of citric acid would hydrolyze pantothenate to pantolactone and β-alanine. After granulation in a high-shear granulator with chopper speed 300–600 rpm, the wet mass is dried in a fluid-bed dryer with inlet air dew point not exceeding −40°C and product temperature below 45°C until the finished granule moisture by USP <921> Method Ia is not more than 0.5%. Compression is performed on a rotary tablet press with external lubrication, and tablet hardness is held at 80–120 N; hardness above 120 N can extend visible disintegration time beyond 3 minutes in 200 mL water at 20°C.

Compliance for release includes Ph. Eur. 0478 for tablets and Ph. Eur. 0499 for granules, with residual moisture determined according to USP <921> Method Ia. Packaging is validated under ICH Q1A(R2) accelerated conditions at 40°C/75% RH for not less than 6 months; desiccant quantity is calculated from the unit-dose water vapor transmission rate of the primary overwrap. Terminal finished product types include single-dose effervescent tablets and double-disc sachets of effervescent granules sealed with aluminum foil overwrap.

Parenteral B-complex ampoules require a different control strategy because calcium D-pantothenate serves both as the active moiety precursor and as a calcium ion donor that can alter electrolyte compatibility. Compounding is performed in controlled rooms meeting ISO 14644-1 Class 8 or higher, and the solution pH is adjusted to 5.5–6.5 with dilute hydrochloric acid or sodium hydroxide before membrane filtration; below pH 4.0 and above pH 7.5, hydrolytic degradation of the amide bond is accelerated, producing pantolactone and β-alanine, and the assay loss increases during terminal sterilization. Concentrations in commercial or compounded B-complex injectables are commonly specified in the range of 5–50 mg/mL calcium D-pantothenate, equivalent to approximately 4.6–46 mg/mL pantothenic acid, although published data for specific branded formulations are limited. The solution is passed through a 0.45 µm prefilter and then a 0.22 µm PVDF or PES membrane whose bacterial retention is qualified under ASTM F838-20, filled into amber glass ampoules or vials under nitrogen overlay, and terminally sterilized at 121°C for 15 min with cycle dwell time; thermal exposure outside the pH 5.5–6.5 window increases degradation within the autoclave load.

Because the molecule contributes elemental calcium at approximately 8.4% by mass, co-infusion with phosphate-containing electrolyte admixtures is not performed without validated calcium–phosphorus solubility screening; the resulting precipitate risk is an operational boundary, not a theoretical issue. Release and stability testing includes USP <1> Injections, USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, USP <790> visible particulates, and USP <232>/<233> elemental impurities according to ICH Q3D. Container closure integrity is verified by vacuum decay per ASTM F2338-09. Terminal finished product types include single-dose intramuscular B-complex vials, intravenous infusion concentrates, and hospital pharmacy compounded total parenteral nutrition additives.

Pediatric Dry Syrup Granulation Without Saccharides

The granulation route for pediatric dry syrups containing calcium D-pantothenate is selected to prevent segregation of the low-dose vitamin from the bulk diluent. In a sachet delivering 5 mg pantothenic acid per 5 mL reconstituted suspension, the sachet fill weight is approximately 2.0 g and the calcium D-pantothenate charge is 5.43 mg, only 0.27% w/w. Because the API is water-soluble, it is dissolved in the granulating fluid rather than dry-mixed when uniformity below 1.0% w/w is required; the solution is sprayed onto a mannitol or xylitol core in a top-spray fluid-bed processor with inlet air at 45–55°C and exhaust humidity monitored to avoid agglomerate formation. The dried granule fraction retained on a 250 µm sieve and passing a 710 µm sieve is filled into sachets under not more than 35% RH to avoid caking; granule uniformity is confirmed by a validated HPLC assay on 10 random sachet samples rather than by USP <905>, which is not applicable to bulk granules.

Compliance for the granule preparation references Ph. Eur. 0499 and USP <921> for moisture, while microbial quality is established through USP <61>/<62> because the product is a nonsterile oral powder. Stability is conducted under ICH Q1A(R2) using semi-permeable sachet material; desiccant inclusion is required if the water vapor transmission rate of the sachet exceeds 0.5 g/m²/day because hygroscopic uptake can reduce rehydration and alter sachet headspace. Terminal finished dosage forms include sugar-free dispersible granules, reconstituted dry syrups with child-resistant closures, and single-dose stick packs for pediatric B-vitamin supplementation.

Because ferrous fumarate and calcium D-pantothenate differ in particle size and moisture sensitivity, prenatal multiple-micronutrient compressed tablets are usually manufactured using a split granulation architecture rather than a single wet mass. Prenatal formulations generally provide 6–10 mg pantothenic acid per daily tablet, corresponding to 6.52–10.87 mg calcium D-pantothenate. In a 900 mg core, this is 0.72–1.21% w/w, placing the material in the low-assay granulation fraction. The pantothenate is dissolved in purified water or an aqueous PVP solution and sprayed onto a microcrystalline cellulose/calcium phosphate carrier, then dried separately before blending with the iron granulation and the trace-mineral premix; this order avoids prolonged contact between calcium D-pantothenate and ferrous fumarate in a wet acidic environment where pH at the granule surface can fall below 4.5.

Tableting is carried out on a rotary press with precompression set to 1.5–3.5 kN and main compression adjusted to produce a 80–140 N core; film coating with an aqueous hydroxypropyl methylcellulose system is operated with inlet air below 60°C to avoid moisture ingress into the pantothenate fraction. Release specifications include USP <905>, USP <2040>, and USP <232>/<233>; the coated core falls under Ph. Eur. 0478. Terminal finished dosage forms include film-coated prenatal tablets, iron–folic acid–B-complex tablets, and labeled prenatal caplets.

When Calcium D-Pantothenate Is Blended with Ascorbic Acid in Powder Premixes

Dry blending of calcium D-pantothenate with ascorbic acid requires an explicit low-moisture environment because the acidic hydrolysis of pantothenate is catalyzed by dissolved hydrogen ions when the blend picks up surface water. For an oral powder premix or multivitamin drink sachet with 25 mg pantothenic acid per 2.0 g dose, calcium D-pantothenate is incorporated at 27.18 mg, or 1.36% w/w. The premix is prepared by geometric dilution: the calcium D-pantothenate is first mixed with an equal mass of anhydrous dextrose or mannitol, then the mixture is passed through a 500 µm stainless steel screen before final blending in a V-blender at 15–25 rpm for 15–20 min. Fumed silica at 0.5–1.0% is added only when flow or caking occurs, and the blend is filled under not more than 30% RH into low water vapor permeation sachets.

Terminal finished product types include single-dose oral powder sachets, vitamin C–B-complex dry drinks, and pharmacy compounding premixes. Stability testing under ICH Q1A(R2) accelerated conditions requires assay and related-substance monitoring at 0, 1, 2, 3, and 6 months to detect degradation not visible to visual inspection; the major hydrolysis product pantolactone is tracked by HPLC with low-wavelength detection at 205 nm. Compliance for the API remains the USP calcium pantothenate monograph, with residual moisture by USP <921>; the finished powder is tested for microbial quality under USP <61>/<62>.